The US Food and Drug Administration has approved a new indication for Cymbalta (duloxetine hydrochloride) to treat chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain.
The German biotech company, 4SC AG, has reported preliminary Phase 2a data for its small molecule drug for inflammatory bowel disease that showed a total response rate of 88.5% in patients who had been dependent on corticosteroids.
Wilex AG as become the latest company to invest in antibody-drug conjugate technology with the proposed acquisition of Heidelberg Pharma AG, a privately-held German company with a conjugate platform.
H. Lundbeck A/S has taken the unusual step of issuing minimum revenue and profit forecasts for the period 2012 to 2014, a time during which it will face increased generic competition and higher product sales and promotion costs.
Shire Plc reported strong third quarter results, partly because it was able to nearly triple sales of two drugs that compete directly with products that Genzyme Corp is having trouble supplying.
GlaxoSmithKline Plc is to pay approximately $60 million upfront for a licensing agreement and equity investment in the US-listed biopharmaceutical company, Amicus Therapeutics Inc, which is developing a product for Fabry disease.
The US Food and Drug Administration has issued a ‘complete response letter’ to Biodel Inc of Danbury, Connecticut rejecting its new drug application for Linjeta, a rapid-acting injectable regular human insulin for Types 1 and 2 diabetes.
MorphoSys AG increased its proprietary research and development spending by 40% in the first nine months of 2010 – an indicator of the growing importance of its portfolio of internally-generated therapeutic antibodies.
Financial results from Sanofi-Aventis for the third quarter and first nine months indicate that the French pharmaceutical company’s strategy of diversifying into developing countries while cutting costs is working well.
Novo Nordisk A/S, the Danish specialist in diabetes products, raised its guidance for 2010 sales and earnings following strong results for the third quarter.